Quarterly faricimab maintenance for neovascular age-related macular degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4, single-centre program gives patients 2–4 initial faricimab loading injections and then attempts a planned quarterly maintenance schedule (every 12–16 weeks) for those who achieve disease inactivity. It enrolls patients over 50 with active subfoveal macular neovascularisation, including both treatment-naïve and recurrent cases, while excluding eyes with recent anti-VEGF, other macular diseases, or recent ocular surgery. The main outcome is stability without recurrence of neovascular activity on the quarterly regimen at a tertiary eye centre in Hong Kong. The work is positioned as a real-world evaluation of a lower-frequency dosing option to reduce treatment burden compared with PRN or treat-and-extend approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects aged over 50 years, neovascular AMD with foveal involvement, both treatment-naïve and recurrent cases. There were no specific criteria for initial best-corrected visual acuity (BCVA). Only active subfoveal MNV are included, including types 1, 2, and 3.

Exclusion Criteria:

* eyes that received any anti-VEGF therapy in the prior six months,
* eyes with other disease entities (e.g., diabetic macula oedema, retinal vein occlusions, central serous chorioretinopathy, myopicmacular neovascularisation),
* concurrent macula laser (except photodynamic therapy) and ocular surgery (e.g., cataract surgery or vitrectomy) in the prior six months and the study period.

Where it's running

• Department of Ophthalmology, United Chrisitian Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Study coordinator: Daniel Ho Tak Wong, FRCOphth (UK)
• Email: WHT454@ha.org.hk
• Phone: +852 3949 3411

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Faricimab for CNV in Presumed Ocular Histoplasmosis Syndrome

  This study tests whether Faricimab can safely and effectively treat choroidal neovascularization linked to presumed ocular histoplasmosis in adults over a 52-week period.

  Recruiting at 2 sites Phase 4 Cincinnati Eye Institute, Southwest Ohio · Cincinnati, Ohio and 1 other locations · NCT07695298

• Early imaging changes with faricimab versus biosimilar ranibizumab for diabetic retinal disease

  This trial will see if faricimab or a biosimilar ranibizumab causes different early OCT and OCTA imaging changes in adults with diabetic retinopathy or diabetic macular edema who need anti-VEGF injections.

  Recruiting Osijek University Hospital · Osijek · NCT07520045

• Personalized treat-and-extend faricimab regimen for treatment-naive polypoidal choroidal vasculopathy

  This tests whether a personalized treat-and-extend dosing schedule of faricimab (Vabysmo) helps people with newly diagnosed polypoidal choroidal vasculopathy keep or improve their vision.

  Recruiting Phase 3 Yeungnam University College of Medicine · Daegu, Namgu · NCT07461441

• RO7823653 injections, alone or with faricimab, for diabetic macular edema

  This research tests injections of RO7823653, given alone or with faricimab, in people with diabetic macular edema to see if the medication is safe and how the eye handles it.

  Recruiting at 12 sites Phase 1 Genentech, Inc. · Peoria, Arizona and 11 other locations · NCT07425522

• Faricimab for subretinal hyper-reflective material in AMD

  This study tests whether Faricimab (Vabysmo) can help reduce subretinal hyper-reflective material in adults with age-related macular degeneration.

  Recruiting at 10 sites Phase 4 Biobizkaia Health Research Institute · Córdoba, Andalusia and 9 other locations · NCT07403825

• See If Faricimab Helps Neovascular Age-related Macular Degeneration

  This study tests whether Faricimab injections every month for 4 months can help adults aged 50 and older with active neovascular AMD in at least one eye.

  Recruiting at 3 sites Phase 4 Asan Medical Center · Seongnam and 4 other locations · NCT07367282

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.